BTX 1801 trial early Q2 2020, page-2

now to all those investors/traders out there lets imagine this scenario for the time being. just imagine. this is a news release from media.

A new stock is about to be listed on the ASX. Its called Botanix Pharmaceuticals. It only has one drug to test in a clinical study BTX 1801. If successful shareholders will reap massive gains.The company is well funded with 30 million cash so any failure will still leave the company with ample funding.

This drug BTX 1801 could eliminate staph from noses. It has massive potential in a market screaming for new anti biotics to combat staph. It is a billion dollar drug if it works. BTX 1801 demonstrates synthetic cannabidiol rapidly kills MRSA bacteria within 10
minutes of exposure, by a novel mechanism of action, and without allowing resistance to develop.

Furthermore, studies conducted by Botanix have shown that BTX 1801 is more effective than the
market leading decolonisation agent, mupirocin, at decolonising MRSA and mupirocin resistance
strains of MRSA were utilized in the industry-accepted pig skin decolonisation model.

This combined with previous work showing that MRSA bacteria lack the ability to develop resistance to cannabidiol,
makes BTX 1801 an ideal candidate for nasal decolonisation of Staph and MRSA for the prevention of
SSIs.

The company will list on March 29 2020 at 10.00am. It has raised $30 million dollars and is debt free.

The CEO said the clinical study can also be completed efficiently and is highly cost effective, as it will
only involve 60 volunteers with a treatment period of five days. Final preparations for the BTX 1801
Phase 2a study are now underway and Botanix expects to enrol its first participants early in 2Q CY2020 with news following shortly on this most exciting new drug.